Trimethylamine N-Oxide Promotes Autoimmunity and a Loss of Vascular Function in Toll-like Receptor 7-Driven Lupus Mice
Authors:
- Cristina González-CorreaCGCristina González-Correa
- Javier MoleónJMJavier Moleón
- Sofía MiñanoSMSofía Miñano
- Néstor de la VisitaciónNVNéstor de la Visitación
- Iñaki Robles-VeraIRIñaki Robles-Vera
- Manuel Gómez-GuzmánManuel Gómez-Guzmán
- Rosario JiménezRJRosario Jiménez
- Miguel RomeroMiguel Romero
- Juan DuarteJuan Duarte
Open Access
- 30 December 2021
- journal article
- research article
- Published by MDPI AG in Antioxidants
- Vol. 11 (1) , 84
Abstract
Plasma levels of trimethylamine N-oxide (TMAO) are elevated in lupus patients. We analyzed the implication of TMAO in autoimmunity and vascular dysfunction of the murine model of systemic lupus erythematosus (SLE) induced by the activation of the Toll-like receptor (TLR)7 with imiquimod (IMQ). Female BALB/c mice were randomly divided into four groups: untreated control mice, control mice treated with the trimethylamine lyase inhibitor 3,3-dimethyl-1-butanol (DMB), IMQ mice, and IMQ mice treated with DMB. The DMB-treated groups were administered the substance in their drinking water for 8 weeks. Treatment with DMB reduced plasma levels of TMAO in mice with IMQ-induced lupus. DMB prevents the development of hypertension, reduces disease progression (plasma levels of anti-dsDNA autoantibodies, splenomegaly, and proteinuria), reduces polarization of T lymphocytes towards Th17/Th1 in secondary lymph organs, and improves endothelial function in mice with IMQ-induced lupus. The deleterious vascular effects caused by TMAO appear to be associated with an increase in vascular oxidative stress generated by increased NADPH oxidase activity, derived in part from the vascular infiltration of Th17/Th1 lymphocytes, and reduced nrf2-driven antioxidant defense. In conclusion, our findings identified the bacterial-derived TMAO as a regulator of immune system, allowing for the development of autoimmunity and endothelial dysfunction in SLE mice.Keywords
Funding Information
- Ministerio de Fomento (SAF2017-84894-R)
- Ministerio de Economía y Competitividad (PID2020-116347RB-I00)
This publication has 56 references indexed in Scilit:
- Mortality and Cardiovascular Burden of Systemic Lupus Erythematosus in a US Population-based CohortThe Journal of Rheumatology, 2014
- Nrf2 suppresses lupus nephritis through inhibition of oxidative injury and the NF-κB-mediated inflammatory responseKidney International, 2014
- Epicutaneous Application of Toll‐like Receptor 7 Agonists Leads to Systemic Autoimmunity in Wild‐Type Mice: A New Model of Systemic Lupus ErythematosusArthritis & Rheumatology, 2013
- Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertensionCardiovascular Research, 2012
- Balance between Regulatory T and Th17 Cells in Systemic Lupus Erythematosus: The Old and the NewJournal of Immunology Research, 2012
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Pro-Inflammatory Effects of Interleukin-17A on Vascular Smooth Muscle Cells Involve NAD(P)H- Oxidase Derived Reactive Oxygen SpeciesJournal of Vascular Research, 2010
- Systemic lupus erythematosus and cardiovascular diseaseLupus, 2008
- Localization and replication of the systemic lupus erythematosus linkage signal at 4p16: interaction with 2p11, 12q24 and 19q13 in European AmericansHuman Genetics, 2006
- Long-Term Inhibition of Rho-Kinase Suppresses Angiotensin II–Induced Cardiovascular Hypertrophy in Rats In VivoCirculation Research, 2003